Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hossein Pakdaman

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cellular and Molecular Neurobiology|July 23, 2020
The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally PathogenicMahsa Pourhamzeh, Mohammad Taghi Joghataei, Soraya Mehrabi, et al.
Scientific Reports|May 4, 2021
Epilepsy lifetime prevalence in Iran: a large population- based national surveyHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
Cellular and Molecular Neurobiology|March 21, 2024
Retraction Note: The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally PathogenicMahsa Pourhamzeh, Mohammad Taghi Joghataei, Soraya Mehrabi, et al.
Medicine|June 19, 2023
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot studyHossein Pakdaman, Koroush Gharagozli, Faezeh Karamiani, et al.
Scientific Reports|January 16, 2024
A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigueAli Amini Harandi, Hossein Pakdaman, Aida Medghalchi, et al.
Current Aging Science|February 27, 2023
A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8-year Follow-up StudyHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
Dementia and Geriatric Cognitive Disorders Extra|April 16, 2015
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled TrialHossein Pakdaman, Ali Amini Harandi, Hamidreza Hatamian, et al.
Neuroimmunomodulation|August 18, 2022
Vascular Endothelial Growth Factor as a Predictive and Prognostic Biomarker for Multiple SclerosisAli Amini Harandi, Fatemeh Siavoshi, Siavash Shirzadeh Barough, et al.
The International Journal of Neuroscience|June 10, 2016
Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in IranHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
The European Journal of Neuroscience|May 5, 2022
P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes modelsAisan Farhadi, Mehdi Totonchi, Seyed Masood Nabavi, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cellular and Molecular Neurobiology|July 23, 2020
The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally PathogenicMahsa Pourhamzeh, Mohammad Taghi Joghataei, Soraya Mehrabi, et al.
Scientific Reports|May 4, 2021
Epilepsy lifetime prevalence in Iran: a large population- based national surveyHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
Cellular and Molecular Neurobiology|March 21, 2024
Retraction Note: The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally PathogenicMahsa Pourhamzeh, Mohammad Taghi Joghataei, Soraya Mehrabi, et al.
Medicine|June 19, 2023
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot studyHossein Pakdaman, Koroush Gharagozli, Faezeh Karamiani, et al.
Scientific Reports|January 16, 2024
A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigueAli Amini Harandi, Hossein Pakdaman, Aida Medghalchi, et al.
Current Aging Science|February 27, 2023
A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8-year Follow-up StudyHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
Dementia and Geriatric Cognitive Disorders Extra|April 16, 2015
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled TrialHossein Pakdaman, Ali Amini Harandi, Hamidreza Hatamian, et al.
Neuroimmunomodulation|August 18, 2022
Vascular Endothelial Growth Factor as a Predictive and Prognostic Biomarker for Multiple SclerosisAli Amini Harandi, Fatemeh Siavoshi, Siavash Shirzadeh Barough, et al.
The International Journal of Neuroscience|June 10, 2016
Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in IranHossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, et al.
The European Journal of Neuroscience|May 5, 2022
P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes modelsAisan Farhadi, Mehdi Totonchi, Seyed Masood Nabavi, et al.
Pageof 6